|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nineteen HLA-A2 positive patients with rising PSA without detectable metastatic disease or local recurrence received 11 HLA-A*0201-restricted and two HLA class II synthetic peptides derived from PC tumor antigens subcutaneously for 18 months or until PSA progression.
|
19267352 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Higher PSA values were not always associated with a pathologic stage of pT3 or greater, and lower levels did not ensure that a tumor was organ-confined.
|
8753736 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PSA levels were significantly correlated with the Gleason score, tumor stage, and lymph node metastasis with Spearman correlation coefficients: 0.612, 0.576, and 0.458.
|
25521481 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA production was high initially, but was markedly reduced when the derivative cell lines were inoculated and allowed to grow long-term in vivo for the establishment of tumors and metastasis, suggesting that unknown host factors derived either from the prostate or the bone can effectively downregulate PSA expression by prostate tumor epithelium.
|
10881018 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Changes in tumour PSA density with stage and grade were assessed by Student's t-test, and its association with biochemical recurrence explored by Kaplan-Meier curves and Cox regression.
|
27120785 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patient features (age, body mass index - BMI, PSA, date of surgery and sexual function), tumor features (tumor stage, Gleason and surgical margins) and followup data (time to reach urinary continence and sexual potency) were the variables collected at 1, 3, 6 and 12 month and every 6 months thereafter.
|
31136108 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In subcutaneous ENZ-R LNCaP xenografts, combinatory treatment of LNP CLU-siRNA plus AR-ASO significantly suppressed tumor growth and serum PSA levels compared with LNP LUC-siRNA (control) and AR-ASO.
|
26106075 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cox proportional hazards regression was utilized to relate FLT uptake and other clinical markers (PSA and tumor size) to progression-free survival.
|
30700328 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reciprocally, PROS1 knockdown inhibited cell invasiveness and migration, caused the growth inhibition of castration-resistant tumor xenograft under androgen-depleted conditions, and potentiated Taxol (a widely prescribed anti-neoplastic agent)-mediated cell death in PC3 cells.
|
27342144 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Positive Claudin-1 immunostaining was associated with favorable tumor features like low pT (p = 0.0032), low Gleason grade (p< 0.0001), and a reduced risk of PSA recurrence (p = 0.0005).
|
31745645 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Relevant data such as age, preoperative serum PSA values, and tumor stage were obtained from 51 patients' with PCa record who underwent radical prostatectomy between January 2010 and March 2014.
|
27085489 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
No significant difference was observed concerning clinical stage, PSA, and tumor grade.
|
10960844 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Both AR expression in the tumor and PSA levels in mouse serum correlated with tumor size.
|
11857028 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.
|
29044297 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder.
|
28117816 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo xenografts of retinoblastoma-deficient tumors exhibited diminished tumor mass, lower PSA kinetics, and decreased tumor growth after treatment with ionizing radiation (P < 0.05).
|
25165096 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To study if prostatic ductal adenocarcinoma (PDA) controlled by Grade Group (GG), PSA, and tumor volume (TV) is an independent predictor of adverse radical prostatectomy (RP) outcomes.
|
31711982 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERG overexpression (ERG+ or ERG-) was determined by immunohistochemistry (IHC) in 1039 radical prostatectomy (RP) tumors and association with PSA, D'Amico risk score, histopathology, biochemical recurrence, body mass index and age of PCa cases was analyzed.
|
23381693 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LOH at 16q23.2 is associated with low stage low grade tumors and lower preoperative PSA, while LOH at 8p22 is more frequent in high stage high grade prostate cancer.
|
16015610 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-10 genotypes were furthermore not associated with tumour characteristics such as histological grade, T stage, PSA levels at diagnosis, or age at diagnosis.
|
17182240 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Myeloid cell receptor tyrosine kinases TYRO3, AXL, and MERTK and their ligands, GAS6 and PROTEIN S, physiologically suppress innate immune responses, including in the tumor microenvironment.
|
31451482 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that tspan13 expression inversely correlates with Gleason score (p=0.01) and PSA preoperative levels (p=0.11) and directly correlates with presence of prostatic intraepithelial neoplasia in tumor tissue (p=0.04).
|
19148481 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, subgroup analysis by testing material demonstrated the significant association between RASSF1A methylation and GS (OR = 3.09, 95% CI 1.92-4.97, P heterogeneity =0.042), PSA level (OR = 2.75, 95% CI 1.67-4.52, P(heterogeneity) = 0.639), and tumor stage (OR = 1.74, 95% CI 1.05-2.87, P(heterogeneity) = 0.026) in tissue rather than urine samples.
|
24353088 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor volume and serum PSA levels were significantly higher in the HFD group than in the LFD group (P<0.001 and P=0.006, respectively).
|
18175332 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study to examine whether the serum LacdiNAc carrying prostate-specific antigen-glycosylation isomer (PSA-Gi) and WFA-reactivity of tumor tissue can be applied as a diagnostic and prognostic marker of prostate cancer (PCa).
|
28134773 |
2017 |